» Articles » PMID: 39329960

Biochemical Pathways Delivering Distinct Glycosphingolipid Patterns in MDA-MB-231 and MCF-7 Breast Cancer Cells

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2024 Sep 27
PMID 39329960
Authors
Affiliations
Soon will be listed here.
Abstract

The complex structure of glycosphingolipids (GSLs) supports their important role in cell function as modulators of growth factor receptors and glutamine transporters in plasma membranes. The aberrant composition of clustered GSLs within signaling platforms, so-called lipid rafts, inevitably leads to tumorigenesis due to disturbed growth factor signal transduction and excessive uptake of glutamine and other molecules needed for increased energy and structural molecule cell supply. GSLs are also involved in plasma membrane processes such as cell adhesion, and their transition converts cells from epithelial to mesenchymal with features required for cell migration and metastasis. Glutamine activates the mechanistic target of rapamycin complex 1 (mTORC1), resulting in nucleotide synthesis and proliferation. In addition, glutamine contributes to the cancer stem cell GD2 ganglioside-positive phenotype in the triple-negative breast cancer cell line MDA-MB-231. Thieno[2,3-]pyridine derivative possesses higher cytotoxicity against MDA-MB-231 than against MCF-7 cells and induces a shift to aerobic metabolism and a decrease in S(6)nLc4Cer GSL-positive cancer stem cells in the MDA-MB-231 cell line. In this review, we discuss findings in MDA-MB-231, MCF-7, and other breast cancer cell lines concerning their differences in growth factor receptors and recent knowledge of the main biochemical pathways delivering distinct glycosphingolipid patterns during tumorigenesis and therapy.

References
1.
Liberti M, Locasale J . The Warburg Effect: How Does it Benefit Cancer Cells?. Trends Biochem Sci. 2016; 41(3):211-218. PMC: 4783224. DOI: 10.1016/j.tibs.2015.12.001. View

2.
Mayer A, Schmidt M, Seeger A, Serras A, Vaupel P, Schmidberger H . GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva. BMC Cancer. 2014; 14:760. PMC: 4210616. DOI: 10.1186/1471-2407-14-760. View

3.
Scott K, Kabbarah O, Liang M, Ivanova E, Anagnostou V, Wu J . GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 2009; 459(7250):1085-90. PMC: 2753613. DOI: 10.1038/nature08109. View

4.
Halder S, Basu S, Lall S, Ganti A, Batra S, Seshacharyulu P . Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?. Expert Opin Ther Targets. 2023; 27(4-5):305-324. PMC: 10330690. DOI: 10.1080/14728222.2023.2218613. View

5.
Derynck R, Weinberg R . EMT and Cancer: More Than Meets the Eye. Dev Cell. 2019; 49(3):313-316. PMC: 7672963. DOI: 10.1016/j.devcel.2019.04.026. View